DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2016/0264934 A1 GALLOURAKIS Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2016/0264934 A1 GALLOURAKIS Et Al US 20160264934A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0264934 A1 GALLOURAKIS et al. (43) Pub. Date: Sep. 15, 2016 (54) METHODS FOR MODULATING AND Publication Classification ASSAYING MI6AIN STEM CELL POPULATIONS (51) Int. Cl. CI2N5/0735 (2006.01) (71) Applicants: THE GENERAL, HOSPITAL AOIN I/02 (2006.01) CORPORATION, Boston, MA (US); CI2O I/68 (2006.01) The Regents of the University of GOIN 33/573 (2006.01) California, Oakland, CA (US) CI2N 5/077 (2006.01) CI2N5/0793 (2006.01) (72) Inventors: Cosmas GIALLOURAKIS, Boston, (52) U.S. Cl. MA (US); Alan C. MULLEN, CPC ............ CI2N5/0606 (2013.01); CI2N5/0657 Brookline, MA (US); Yi XING, (2013.01); C12N5/0619 (2013.01); C12O Torrance, CA (US) I/6888 (2013.01); G0IN33/573 (2013.01); A0IN I/0226 (2013.01); C12N 2501/72 (73) Assignees: THE GENERAL, HOSPITAL (2013.01); C12N 2506/02 (2013.01); C12O CORPORATION, Boston, MA (US); 2600/158 (2013.01); C12Y 201/01062 The Regents of the University of (2013.01); C12Y 201/01 (2013.01) California, Oakland, CA (US) (57) ABSTRACT (21) Appl. No.: 15/067,780 The present invention generally relates to methods, assays and kits to maintain a human stem cell population in an (22) Filed: Mar 11, 2016 undifferentiated state by inhibiting the expression or function of METTL3 and/or METTL4, and mA fingerprint methods, assays, arrays and kits to assess the cell state of a human stem Related U.S. Application Data cell population by assessing mA levels (e.g. mA peak inten (60) Provisional application No. 62/131,490, filed on Mar. sities) of a set of target genes disclosed herein to determine if 11, 2015. the stem cell is in an undifferentiated or differentiated state. Patent Application Publication Sep. 15, 2016 Sheet 2 of 13 US 2016/0264934 A1 X- & FG. 2B FG, 2C ACN s ACN fic lett3 iype via FIG. 2E FG. 2F g 8 hasg g 08 3 -i-. is 3. s C - - 883-i- if 3 : s s 2 c - a. ;3. : Six a w kE E. : s as E a s 33is is s 8: isN see * : s i $2 s Patent Application Publication Sep. 15, 2016 Sheet 3 of 13 US 2016/0264934 A1 F.G. 3A 88 Narc 33 8 : 50 -. 8 3 3: 8. W 33 is: SS S. & E. c 8 i. s: 30 : g aw& " is a 20 3 4 s: is 8.3. is 10 a c 2 8 && Š.s: FG. 3B iQ sri A {E} 3. a. 80 3 c ; is $ 503 s s : 9 8 S. 4 Aay 8 3.: saE. i.; SSes 30 3.g iss is: 3 sx 20 asa as . t R s 838. F.G. 3D &:::::y: 3. g a 38 -------8 33.--------------------------- w838 ye ie:S F.G. 3E s: Patent Application Publication Sep. 15, 2016 Sheet 4 of 13 US 2016/0264934 A1 FG. 4A FG. AB & 838 & 3A RP : 8.-- 8 & ...-a-...--...------...-------------------...-------------------------. 1.s x $ 8. s s: s a. xy 3. : l a. š : - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - ------- - - - - - - - - - - - - - - - -k . & 3: s ; ---8. - : s 8 s 3g2 33.3%. 38te:8:ty atog FG. AD FIG. 4C fat gets S. & its aba RNA sex. 8; Riccie.8 Boss a risihyatic: pya:32 ki3.3s pya:38 x8.3 FG. A.E x- F.G. 4F mA-8-Nanostring RA ests 8er tiavoiridot treat sett 8 Wild type 32. c B.S OS is x &lett:3 -i- Qs 3 8.8 85 3. E3 8 3.4 83.3 8s 8 V . 3.3 $3.3 c $ 3. 4 3 : 0.2 3. 8 t . 2. 5 3.3 B {} Narog Octa 8 Wild typs & Metti3 :- Patent Application Publication Sep. 15, 2016 Sheet 5 of 13 US 2016/0264934 A1 F.G. 5A 8: 8:8 F.G. SD ----------&-. F.G. SE 3. s 8 & s s 3. : s s F.G. SG F.G. SH FIG. 5 F.G. 5, Patent Application Publication Sep. 15, 2016 Sheet 6 of 13 US 2016/0264934 A1 & rSSC & ESS |----+--~~~~~~~~~ aga is: 88. s F.G. 6D F.G. 6E Rossa Sesii. iiia Speci 8. FIG. 6F is: 88s & .......S.S.C. A38:8 w kissets: 8kse: Patent Application Publication Sep. 15, 2016 Sheet 8 of 13 US 2016/0264934 A1 FIG. 8 Patent Application Publication Sep. 15, 2016 Sheet 9 of 13 US 2016/0264934 A1 Ajacg FIG.9B se k s :::::: 8 : SO FIG. 9F Excisgth its 8: 8. 88scing s & 8 hSassass -8-38.-2S 250 583. 750. 5' UTai cis 3' uri; Esince cast exor-exxiiikoi by FG. 9. RNA Polymerase E 3st Eartile w 2st quartile & st cartile s 3.3 -- fr&A frtified Patent Application Publication Sep. 15, 2016 Sheet 10 of 13 US 2016/0264934 A1 F.G. 10A fiss448 3 3.8 mala-Han SRNA taigeied region gr8A targeted fegion Adeiti3 / S. gasysexes s . Seri areas 38ere stated Eferentiate: six type & Aitk: -- i.18:34atti-i- is FIG. OF FG. LOG FIG. OH 5 exile.iii.333 as: -late:3:2 s g is 4.8 i. s. 3 aš& s ;: 3s is . s: 3 0:5 E3 Š s esses Asti ges 8 Patent Application Publication Sep. 15, 2016 Sheet 11 of 13 US 2016/0264934 A1 FIG. 11A KANS: i FG, 11B mRNA level in Metii3 -f- derived tumors compared to wildtype derived tumors. O 35 3. s ; : e a r 3. 4. 3. Patent Application Publication Sep. 15, 2016 Sheet 12 of 13 FG, 2A LNCE:08:MA s LINQRoš 50 Set isfai exis asses FG, 12E it:8 scietscore Patent Application Publication Sep. 15, 2016 Sheet 13 of 13 US 2016/0264934 A1 F.G. 13A F.G. 13D ***&&$33.33% F.G. 13B F.G. 13E FG, 13C 28 23.3 82.3.g US 2016/0264934 A1 Sep. 15, 2016 METHODS FOR MODULATING AND functional characterization of the YTH domain family of ASSAYING MI6AN STEM CELL “reader proteins which specifically bind mA sites and POPULATIONS recruit the linked transcripts to RNA decay bodies (Kang et al., 2014; Wang et al., 2014a). CROSS REFERENCE TO RELATED 0006 Whereas the DNA methylome undergoes dramatic APPLICATIONS reprogramming during early embryonic life, the developmen tal origins and functions of mA in mammals are incom 0001. This application claims benefit under 35 U.S.C. pletely understood. Furthermore, the degree of evolutionary S119(e) of U.S. Provisional Application No. 62/131,490 filed conservation of mA sites is not known in ESCs. Therefore, on Mar. 11, 2015, the contents of each of which are incorpo there is a need in the art for effective and efficient methods for rated herein by reference in their entireties. assessing mA mRNA methylome in stem cells and human GOVERNMENT SUPPORT stem cells, for example, to characterize and validate cells, including human pluripotent stem cells, and for determining 0002 This invention was made, in part, with government the quality and cell State of a human stem cell populations, support under NIH Grant Number DK090122 awarded by e.g., prior to its use, e.g., in therapeutic administration, dis National Institutes of Health. The Government of the U.S. has ease modeling, drug development and screening and toxicity certain rights in the invention. assays etc. FIELD OF THE INVENTION SUMMARY OF THE INVENTION 0003. The present invention relates to arrays and methods 0007. The present invention is directed to, in part, meth for characterizing stem cell populations assessing transcrip ods, compositions and kits to maintain a stem cell population, tionwide distribution of mA methylation to characterize and Such as a human stem cell population, in an undifferentiated permit selection of stem cell lines for further use, and to state, comprising contacting the stem cell population with an modulation of METTL3, e.g., inhibition to maintain stem inhibitor of METTL3 or METTL4. In some embodiments, cells in an undifferentiated state or activation of METTL3 to the methods, compositions and kits as disclosed herein relate promote differentiation along endoderm lineages. to methods to prevent a stem cell population differentiating along an endoderm lineage. Other aspects of the technology BACKGROUND OF THE INVENTION described herein relates to methods, compositions and kits to 0004 Reversible chemical modifications on messenger promote a stem cell population to differentiate along an endo RNAS have emerged as prevalent phenomena that may open derm lineage. Moreover, another aspect of the technology a new field of “RNA epigenetics', akin to the diverse roles described herein relates to methods, assays, arrays and kits that DNA modifications play in epigenetics (reviewed by Fu for performing mA analysis of RNA from stem cell popula and He, 2012; Sibbritt et al., 2013). N6-methyl-adenosine tions to characterize the cell state of the cell population, (mA) is the most prevalent modification of mRNAs in which can be used, for example, as a quality control for the Somatic cells, and dysregulation of this modification has stem cell population. In some embodiments, the stem cell already been linked to obesity, cancer, and other human dis population is a human stem cell population, e.g., a hESC cell eases (Sibbritt et al., 2013). mA has been observed in a wide population or other human stem cell line. range of organisms, and the known methylation complex is 10008 N6-methyl-adenosine (mA) is the most abundant conserved across eukaryotes (Bokar et al., 1997, Bujnicki, covalent modification on messenger RNAS in Somatic cells 2002 #375). In budding yeast, the mA methylation program and is linked to human diseases, but its functions in mamma is activated by starvation and required for sporulation (Agar lian development are poorly understood.
Load more

Recommended publications
  • Small Cell Ovarian Carcinoma: Genomic Stability and Responsiveness to Therapeutics
    Gamwell et al. Orphanet Journal of Rare Diseases 2013, 8:33 http://www.ojrd.com/content/8/1/33 RESEARCH Open Access Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics Lisa F Gamwell1,2, Karen Gambaro3, Maria Merziotis2, Colleen Crane2, Suzanna L Arcand4, Valerie Bourada1,2, Christopher Davis2, Jeremy A Squire6, David G Huntsman7,8, Patricia N Tonin3,4,5 and Barbara C Vanderhyden1,2* Abstract Background: The biology of small cell ovarian carcinoma of the hypercalcemic type (SCCOHT), which is a rare and aggressive form of ovarian cancer, is poorly understood. Tumourigenicity, in vitro growth characteristics, genetic and genomic anomalies, and sensitivity to standard and novel chemotherapeutic treatments were investigated in the unique SCCOHT cell line, BIN-67, to provide further insight in the biology of this rare type of ovarian cancer. Method: The tumourigenic potential of BIN-67 cells was determined and the tumours formed in a xenograft model was compared to human SCCOHT. DNA sequencing, spectral karyotyping and high density SNP array analysis was performed. The sensitivity of the BIN-67 cells to standard chemotherapeutic agents and to vesicular stomatitis virus (VSV) and the JX-594 vaccinia virus was tested. Results: BIN-67 cells were capable of forming spheroids in hanging drop cultures. When xenografted into immunodeficient mice, BIN-67 cells developed into tumours that reflected the hypercalcemia and histology of human SCCOHT, notably intense expression of WT-1 and vimentin, and lack of expression of inhibin. Somatic mutations in TP53 and the most common activating mutations in KRAS and BRAF were not found in BIN-67 cells by DNA sequencing.
    [Show full text]
  • A Comparative Analysis of Transcribed Genes in the Mouse Hypothalamus and Neocortex Reveals Chromosomal Clustering
    A comparative analysis of transcribed genes in the mouse hypothalamus and neocortex reveals chromosomal clustering Wee-Ming Boon*, Tim Beissbarth†, Lavinia Hyde†, Gordon Smyth†, Jenny Gunnersen*, Derek A. Denton*‡, Hamish Scott†, and Seong-Seng Tan* *Howard Florey Institute, University of Melbourne, Parkville 3052, Australia; and †Genetics and Bioinfomatics Division, Walter and Eliza Hall Institute of Medical Research, Royal Parade, Parkville 3050, Australia Contributed by Derek A. Denton, August 26, 2004 The hypothalamus and neocortex are subdivisions of the mamma- representing all of the genes that are expressed (qualitative and lian forebrain, and yet, they have vastly different evolutionary quantitative) in the hypothalamus and neocortex under standard histories, cytoarchitecture, and biological functions. In an attempt conditions. to define these attributes in terms of their genetic activity, we have In the current study, we describe the use of the Serial Analysis compared their genetic repertoires by using the Serial Analysis of of Gene Expression (SAGE) database, which allows simulta- Gene Expression database. From a comparison of 78,784 hypothal- neous detection of the expression levels of the entire genome amus tags with 125,296 neocortical tags, we demonstrate that each without a priori knowledge of gene sequences (13). SAGE takes structure possesses a different transcriptional profile in terms of advantage of the fact that a small sequence tag taken from a gene ontological characteristics and expression levels. Despite its defined position within the transcript is sufficient to identify the more recent evolutionary history, the neocortex has a more com- gene (from known cDNA or EST sequences), and up to 40 tags plex pattern of gene activity.
    [Show full text]
  • Identification of the Binding Partners for Hspb2 and Cryab Reveals
    Brigham Young University BYU ScholarsArchive Theses and Dissertations 2013-12-12 Identification of the Binding arP tners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactions and Non- Redundant Roles for Small Heat Shock Proteins Kelsey Murphey Langston Brigham Young University - Provo Follow this and additional works at: https://scholarsarchive.byu.edu/etd Part of the Microbiology Commons BYU ScholarsArchive Citation Langston, Kelsey Murphey, "Identification of the Binding Partners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactions and Non-Redundant Roles for Small Heat Shock Proteins" (2013). Theses and Dissertations. 3822. https://scholarsarchive.byu.edu/etd/3822 This Thesis is brought to you for free and open access by BYU ScholarsArchive. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of BYU ScholarsArchive. For more information, please contact [email protected], [email protected]. Identification of the Binding Partners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactions and Non-Redundant Roles for Small Heat Shock Proteins Kelsey Langston A thesis submitted to the faculty of Brigham Young University in partial fulfillment of the requirements for the degree of Master of Science Julianne H. Grose, Chair William R. McCleary Brian Poole Department of Microbiology and Molecular Biology Brigham Young University December 2013 Copyright © 2013 Kelsey Langston All Rights Reserved ABSTRACT Identification of the Binding Partners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactors and Non-Redundant Roles for Small Heat Shock Proteins Kelsey Langston Department of Microbiology and Molecular Biology, BYU Master of Science Small Heat Shock Proteins (sHSP) are molecular chaperones that play protective roles in cell survival and have been shown to possess chaperone activity.
    [Show full text]
  • BMC Genomics Biomed Central
    BMC Genomics BioMed Central Research article Open Access The functional modulation of epigenetic regulators by alternative splicing Sergio Lois1,2, Noemí Blanco1,2, Marian Martínez-Balbás*1,2 and Xavier de la Cruz*2,3 Address: 1Instituto de Biología Molecular de Barcelona. CID. Consejo Superior de Investigaciones Científicas (CSIC); 08028 Barcelona, Spain, 2Institut de Recerca Biomèdica-PCB; 08028 Barcelona, Spain and 3Institució Catalana de Recerca i Estudis Avançats (ICREA); Barcelona, Spain Email: Sergio Lois - [email protected]; Noemí Blanco - [email protected]; Marian Martínez-Balbás* - [email protected]; Xavier de la Cruz* - [email protected] * Corresponding authors Published: 25 July 2007 Received: 24 April 2007 Accepted: 25 July 2007 BMC Genomics 2007, 8:252 doi:10.1186/1471-2164-8-252 This article is available from: http://www.biomedcentral.com/1471-2164/8/252 © 2007 Lois et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Epigenetic regulators (histone acetyltransferases, methyltransferases, chromatin- remodelling enzymes, etc) play a fundamental role in the control of gene expression by modifying the local state of chromatin. However, due to their recent discovery, little is yet known about their own regulation. This paper addresses this point, focusing on alternative splicing regulation, a mechanism already known to play an important role in other protein families, e.g. transcription factors, membrane receptors, etc.
    [Show full text]
  • Harnessing Gene Expression Profiles for the Identification of Ex Vivo Drug
    cancers Article Harnessing Gene Expression Profiles for the Identification of Ex Vivo Drug Response Genes in Pediatric Acute Myeloid Leukemia David G.J. Cucchi 1 , Costa Bachas 1 , Marry M. van den Heuvel-Eibrink 2,3, Susan T.C.J.M. Arentsen-Peters 3, Zinia J. Kwidama 1, Gerrit J. Schuurhuis 1, Yehuda G. Assaraf 4, Valérie de Haas 3 , Gertjan J.L. Kaspers 3,5 and Jacqueline Cloos 1,* 1 Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands; [email protected] (D.G.J.C.); [email protected] (C.B.); [email protected] (Z.J.K.); [email protected] (G.J.S.) 2 Department of Pediatric Oncology/Hematology, Erasmus MC–Sophia Children’s Hospital, 3015 CN Rotterdam, The Netherlands; [email protected] 3 Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands; [email protected] (S.T.C.J.M.A.-P.); [email protected] (V.d.H.); [email protected] (G.J.L.K.) 4 The Fred Wyszkowski Cancer Research, Laboratory, Department of Biology, Technion-Israel Institute of Technology, 3200003 Haifa, Israel; [email protected] 5 Emma’s Children’s Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Pediatric Oncology, 1081 HV Amsterdam, The Netherlands * Correspondence: [email protected] Received: 21 April 2020; Accepted: 12 May 2020; Published: 15 May 2020 Abstract: Novel treatment strategies are of paramount importance to improve clinical outcomes in pediatric AML. Since chemotherapy is likely to remain the cornerstone of curative treatment of AML, insights in the molecular mechanisms that determine its cytotoxic effects could aid further treatment optimization.
    [Show full text]
  • Defining Functional Interactions During Biogenesis of Epithelial Junctions
    ARTICLE Received 11 Dec 2015 | Accepted 13 Oct 2016 | Published 6 Dec 2016 | Updated 5 Jan 2017 DOI: 10.1038/ncomms13542 OPEN Defining functional interactions during biogenesis of epithelial junctions J.C. Erasmus1,*, S. Bruche1,*,w, L. Pizarro1,2,*, N. Maimari1,3,*, T. Poggioli1,w, C. Tomlinson4,J.Lees5, I. Zalivina1,w, A. Wheeler1,w, A. Alberts6, A. Russo2 & V.M.M. Braga1 In spite of extensive recent progress, a comprehensive understanding of how actin cytoskeleton remodelling supports stable junctions remains to be established. Here we design a platform that integrates actin functions with optimized phenotypic clustering and identify new cytoskeletal proteins, their functional hierarchy and pathways that modulate E-cadherin adhesion. Depletion of EEF1A, an actin bundling protein, increases E-cadherin levels at junctions without a corresponding reinforcement of cell–cell contacts. This unexpected result reflects a more dynamic and mobile junctional actin in EEF1A-depleted cells. A partner for EEF1A in cadherin contact maintenance is the formin DIAPH2, which interacts with EEF1A. In contrast, depletion of either the endocytic regulator TRIP10 or the Rho GTPase activator VAV2 reduces E-cadherin levels at junctions. TRIP10 binds to and requires VAV2 function for its junctional localization. Overall, we present new conceptual insights on junction stabilization, which integrate known and novel pathways with impact for epithelial morphogenesis, homeostasis and diseases. 1 National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK. 2 Computing Department, Imperial College London, London SW7 2AZ, UK. 3 Bioengineering Department, Faculty of Engineering, Imperial College London, London SW7 2AZ, UK. 4 Department of Surgery & Cancer, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Evidence for Differential Alternative Splicing in Blood of Young Boys With
    Stamova et al. Molecular Autism 2013, 4:30 http://www.molecularautism.com/content/4/1/30 RESEARCH Open Access Evidence for differential alternative splicing in blood of young boys with autism spectrum disorders Boryana S Stamova1,2,5*, Yingfang Tian1,2,4, Christine W Nordahl1,3, Mark D Shen1,3, Sally Rogers1,3, David G Amaral1,3 and Frank R Sharp1,2 Abstract Background: Since RNA expression differences have been reported in autism spectrum disorder (ASD) for blood and brain, and differential alternative splicing (DAS) has been reported in ASD brains, we determined if there was DAS in blood mRNA of ASD subjects compared to typically developing (TD) controls, as well as in ASD subgroups related to cerebral volume. Methods: RNA from blood was processed on whole genome exon arrays for 2-4–year-old ASD and TD boys. An ANCOVA with age and batch as covariates was used to predict DAS for ALL ASD (n=30), ASD with normal total cerebral volumes (NTCV), and ASD with large total cerebral volumes (LTCV) compared to TD controls (n=20). Results: A total of 53 genes were predicted to have DAS for ALL ASD versus TD, 169 genes for ASD_NTCV versus TD, 1 gene for ASD_LTCV versus TD, and 27 genes for ASD_LTCV versus ASD_NTCV. These differences were significant at P <0.05 after false discovery rate corrections for multiple comparisons (FDR <5% false positives). A number of the genes predicted to have DAS in ASD are known to regulate DAS (SFPQ, SRPK1, SRSF11, SRSF2IP, FUS, LSM14A). In addition, a number of genes with predicted DAS are involved in pathways implicated in previous ASD studies, such as ROS monocyte/macrophage, Natural Killer Cell, mTOR, and NGF signaling.
    [Show full text]
  • Proteomics Provides Insights Into the Inhibition of Chinese Hamster V79
    www.nature.com/scientificreports OPEN Proteomics provides insights into the inhibition of Chinese hamster V79 cell proliferation in the deep underground environment Jifeng Liu1,2, Tengfei Ma1,2, Mingzhong Gao3, Yilin Liu4, Jun Liu1, Shichao Wang2, Yike Xie2, Ling Wang2, Juan Cheng2, Shixi Liu1*, Jian Zou1,2*, Jiang Wu2, Weimin Li2 & Heping Xie2,3,5 As resources in the shallow depths of the earth exhausted, people will spend extended periods of time in the deep underground space. However, little is known about the deep underground environment afecting the health of organisms. Hence, we established both deep underground laboratory (DUGL) and above ground laboratory (AGL) to investigate the efect of environmental factors on organisms. Six environmental parameters were monitored in the DUGL and AGL. Growth curves were recorded and tandem mass tag (TMT) proteomics analysis were performed to explore the proliferative ability and diferentially abundant proteins (DAPs) in V79 cells (a cell line widely used in biological study in DUGLs) cultured in the DUGL and AGL. Parallel Reaction Monitoring was conducted to verify the TMT results. γ ray dose rate showed the most detectable diference between the two laboratories, whereby γ ray dose rate was signifcantly lower in the DUGL compared to the AGL. V79 cell proliferation was slower in the DUGL. Quantitative proteomics detected 980 DAPs (absolute fold change ≥ 1.2, p < 0.05) between V79 cells cultured in the DUGL and AGL. Of these, 576 proteins were up-regulated and 404 proteins were down-regulated in V79 cells cultured in the DUGL. KEGG pathway analysis revealed that seven pathways (e.g.
    [Show full text]
  • Downloaded from [266]
    Patterns of DNA methylation on the human X chromosome and use in analyzing X-chromosome inactivation by Allison Marie Cotton B.Sc., The University of Guelph, 2005 A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY in The Faculty of Graduate Studies (Medical Genetics) THE UNIVERSITY OF BRITISH COLUMBIA (Vancouver) January 2012 © Allison Marie Cotton, 2012 Abstract The process of X-chromosome inactivation achieves dosage compensation between mammalian males and females. In females one X chromosome is transcriptionally silenced through a variety of epigenetic modifications including DNA methylation. Most X-linked genes are subject to X-chromosome inactivation and only expressed from the active X chromosome. On the inactive X chromosome, the CpG island promoters of genes subject to X-chromosome inactivation are methylated in their promoter regions, while genes which escape from X- chromosome inactivation have unmethylated CpG island promoters on both the active and inactive X chromosomes. The first objective of this thesis was to determine if the DNA methylation of CpG island promoters could be used to accurately predict X chromosome inactivation status. The second objective was to use DNA methylation to predict X-chromosome inactivation status in a variety of tissues. A comparison of blood, muscle, kidney and neural tissues revealed tissue-specific X-chromosome inactivation, in which 12% of genes escaped from X-chromosome inactivation in some, but not all, tissues. X-linked DNA methylation analysis of placental tissues predicted four times higher escape from X-chromosome inactivation than in any other tissue. Despite the hypomethylation of repetitive elements on both the X chromosome and the autosomes, no changes were detected in the frequency or intensity of placental Cot-1 holes.
    [Show full text]
  • 1 UST College of Science Department of Biological Sciences
    UST College of Science Department of Biological Sciences 1 Pharmacogenomics of Myofascial Pain Syndrome An Undergraduate Thesis Submitted to the Department of Biological Sciences College of Science University of Santo Tomas In Partial Fulfillment of the Requirements for the Degree of Bachelor of Science in Biology Jose Marie V. Lazaga Marc Llandro C. Fernandez May 2021 UST College of Science Department of Biological Sciences 2 PANEL APPROVAL SHEET This undergraduate research manuscript entitled: Pharmacogenomics of Myofascial Pain Syndrome prepared and submitted by Jose Marie V. Lazaga and Marc Llandro C. Fernandez, was checked and has complied with the revisions and suggestions requested by panel members after thorough evaluation. This final version of the manuscript is hereby approved and accepted for submission in partial fulfillment of the requirements for the degree of Bachelor of Science in Biology. Noted by: Asst. Prof. Marilyn G. Rimando, PhD Research adviser, Bio/MicroSem 602-603 Approved by: Bio/MicroSem 603 panel member Bio/MicroSem 603 panel member Date: Date: UST College of Science Department of Biological Sciences 3 DECLARATION OF ORIGINALITY We hereby affirm that this submission is our own work and that, to the best of our knowledge and belief, it contains no material previously published or written by another person nor material to which a substantial extent has been accepted for award of any other degree or diploma of a university or other institute of higher learning, except where due acknowledgement is made in the text. We also declare that the intellectual content of this undergraduate research is the product of our work, even though we may have received assistance from others on style, presentation, and language expression.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]